Table 14Comparison of modeled univariate continuous odds ratios (OR) for PCA3 and tPSA in matched studies

Study Author, YearaNPCA3 Regression CoefficientsPCA3 OR @25th CentilePCA3 OR @75th CentileRatio AtPSA Regression CoefficientstPSA OR @25th CentiletPSA OR @75th CentileRatio BRatio (A/B)
Perdona31, 2011c2180.029561.778.754.930.229523.489.02.501.97
de la Taille95, 2011c5160.019801.433.092.160.113331.74b8.0b1.571.38
Aubin91, 2010 c1,0720.018821.312.141.630.01882----
Cao94, 2011 c1310.07232---0.07232----

N = number; OR = odds ratio; PCA3 = prostate cancer antigen 3 gene; tPSA = total prostate specific antigen

a

Both studies used in the analysis only included patients in the tPSA “grey zone.” Rows 1-3 are shaded.

b

Ratios A and B are ratios of ORs at 25th and 75th centiles.

c

These studies reported insufficient information to compute and/or compare Ratios A and B.

Both studies used in the analysis only included patients in the tPSA “grey zone.” Rows 1-3 are shaded.

Ratios A and B are ratios of ORs at 25th and 75th centiles.

These studies reported insufficient information to compute and/or compare Ratios A and B.

From: Results

Cover of PCA3 Testing for the Diagnosis and Management of Prostate Cancer
PCA3 Testing for the Diagnosis and Management of Prostate Cancer [Internet].
Comparative Effectiveness Reviews, No. 98.
Bradley LA, Palomaki G, Gutman S, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.